Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
POLYPHEM: Short-term interruption vs continuous anticoagulation in colorectal polypectomy
2024-512194-27-01Phase 4Authorised
- Sponsor
- Ramón y Cajal University Hospital
- Start
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of acenocoumarol, warfarin, dabigatran, edoxaban, apixaban and 1 more in venous thromboembolism (VTE), Atrial fibrillation (AFib) and thromboembolism (2 arms), sponsored by Ramón y Cajal University Hospital. Primary endpoint: Occurrence of haemorrhage events post-polypectomy. Planned start Jun 2024; status: authorised.
02
Drugs
acenocoumarolwarfarindabigatranedoxabanapixaban
03
Conditions
venous thromboembolism (VTE)Atrial fibrillation (AFib)thromboembolism
Beyond the preview
Go deeper on 2024-512194-27-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512194-27-01.